Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors

ACS Medicinal Chemistry Letters

Volumn 8, Issue 2, 2017, Pages 185-190

  Li, Zhe ^a   Partridge, James ^a   Silva Garcia, Abel ^a   Rademacher, Peter ^a   Betz, Andreas ^a   Xu, Qing ^a   Sham, Hing ^a   Hu, Yunjin ^b   Shan, Yuqing ^b   Liu, Bin ^b   Zhang, Ying ^b   Shi, Haijuan ^b   Xu, Qiong ^b   Ma, Xubo ^b   Zhang, Li ^b  

^a Global Blood Therapeutics ^*  (United States)

^b PHARMARON   (United States)

Author keywords

Hereditary angioedema; macrocycle; plasma kallikrein; protease inhibitor; structure based design

Indexed keywords

KALLIKREIN INHIBITOR; MACROCYCLIC COMPOUND;

ARTICLE; COCRYSTAL STRUCTURE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IC50; ISOMER; PRIORITY JOURNAL;

EID: 85013765976     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00384     Document Type: Article

References (17)

1. Bryant, J. W.; Shariat-Madar, Z. Human plasma kallikrein kinin system: physiological and biochemical parameters Cardiovasc. Hematol. Agents Med. Chem. 2009, 7, 234-50 10.2174/187152509789105444
2. Kaplan, A. P. Bradykinin and the Pathogenesis of Hereditary Angioedema World Allergy Organ. J. 2011, 4, 73-75 10.1097/WOX.0b013e318216b7b2
3. Maas, C.; Oschatz, C.; Renne, T. The plasma contact system 2.0 Semin. Thromb. Hemostasis 2011, 37, 375-38 10.1055/s-0031-1276586
4. Levy, J. H.; Freiberger, D. J.; Roback, J. Hereditary angioedema: current and emerging treatment options Anesth. Analg. 2010, 110, 1271-1280 10.1213/ANE.0b013e3181d7ac98
5. Schneider, L.; Lumry, W.; Vegh, A.; Williams, A. H.; Schmalbach, T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor J. Allergy Clin. Immunol. 2007, 120, 416-422 10.1016/j.jaci.2007.04.028
6. Chyung, Y.; Vince, B.; Iarrobino, B.; Sexton, D.; Kenniston, J.; Faucette, R.; TenHoor, C.; Stolz, L. E.; Stevens, C.; Biedenkapp, J.; Adelman, B. A phase 1 study investigating DX-2930 in healthy subjects Ann. Allergy, Asthma, Immunol. 2014, 113, 460-466 10.1016/j.anai.2014.05.028
7. Aygören-Pürsün, E.; Magerl, M.; Graff, J.; Martinez-Saguer, I.; Kreuz, W.; Longhurst, H.; Nasr, I.; Bas, M.; Straßen, U.; Fang, L.; Cornpropst, M.; Dobo, S.; Collis, P.; Sheridan, W. P.; Maurer, M. Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat J. Allergy Clin. Immunol. 2016, 138, 934-936 10.1016/j.jaci.2016.03.043
8. Cornpropst, M.; Dobo, S.; Collier, J.; Rose, A.; Wilson, R.; Babu, Y. S.; Collis, P.; Zong, J.; Sheridan, W. P. BCX7353, a Potent Inhibitor of Plasma Kallikrein, Shows Sustained Maximal Enzyme Inhibition when Dosed Orally Once Daily: Results from a Phase I Trial in Healthy Subjects. AAAAI Annual Meeting, March 3-8, 2016, Los Angeles, CA.
9. Brandl, T.; Flohr, S.; Kopec, S.; Lachal, J.; Markert, C.; Namoto, K.; Nganga, P.; Pirard, B.; Renatus, M.; Sedrani, R.; Zoller, T. N-((6-Amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein. WO2012017020A1, February 12, 2012.
10. Partridge, J.; Choy, R.; Li, Z. Manuscript in preparation.
11. Kobayashi, T.; Suemasa, A.; Igawa, A.; Ide, S.; Fukuda, H.; Abe, H.; Arisawa, M.; Minami, M.; Shuto, S. Conformationally Restricted GABA with Bicyclo[3.1.0]hexane Backbone as the First Highly Selective BGT-1 Inhibitor ACS Med. Chem. Lett. 2014, 5, 889-893 10.1021/ml500134k
12. Spear, K. L.; Brown, M. S.; Reinhard, M. J.; McMahon, E. G.; Olins, G. M.; Palomo, M. A.; Patton, D. R. Conformational Restriction of Angiotensin II: Cyclic Analogues Having High Potency J. Med. Chem. 1990, 33, 1935-1940 10.1021/jm00169a019
13. El Bakali, J.; Muccioli, G. G.; Body-Malapel, M.; Djouina, M.; Klupsch, F.; Ghinet, A.; Barczyk, A.; Renault, N.; Chavatte, P.; Desreumaux, P.; Lambert, D. M.; Millet, R. Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis ACS Med. Chem. Lett. 2015, 6, 198-203 10.1021/ml500439x
14. Molecular Operating Environment (MOE), 2014.09; Chemical Computing Group Inc., Montreal, QC, Canada, 2014.
15. Fu, G. C.; Grubbs, R. H. The Application of Catalytic Ring-Closing Olefin Metathesis to the Synthesis of Unsaturated Oxygen Heterocycles J. Am. Chem. Soc. 1992, 114, 5426-5427 10.1021/ja00039a065
16. Fu, G. C.; Grubbs, R. H. Synthesis of Nitrogen Heterocycles via Catalytic Ring Closing Metathesis of Dienes J. Am. Chem. Soc. 1992, 114, 7324-7325 10.1021/ja00044a070
17. Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Synthesis and Activity of a New Generation of Ruthenium-Based Olefin Metathesis Catalysts Coordinated with 1,3-Dimesityl-4,5-dihydroimidazol-2-ylidene Ligands Org. Lett. 1999, 1, 953-956 10.1021/ol990909q